Optimizing Patient-centred Outcomes Using Opioid Minimization Strategies: The OPUS Anesthesia Pilot Trial

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

October 31, 2027

Conditions
AnesthesiaAnesthesia ComplicationSurgeryQuality of LifePain, PostoperativeAnesthesia MorbidityFeasibility StudiesPatient-centredness
Interventions
DRUG

Dexmedetomidine

"Intravenous bolus: between 0.2 and 0.5 mcg/kg.~followed by~Intravenous infusion: ranging from 0.2 to 0.7 mcg/kg/h to the discretion of the attending anesthesiologist.~Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure."

DRUG

lidocaine

"Intravenous bolus: between 0.5 and 1.5 mg/kg.~followed by~Intravenous infusion: ranging from 0.5 to 2.0 mg/kg/h to the discretion of the attending anesthesiologist.~Bolus will be initiated prior to surgical incision and infusion will be stopped at wound closure."

OTHER

control group

Usual care where systemic dexmedetomidine is not allowed and systemic lidocaine is permitted only for the prevention or treatment of propofol injection pain.

Trial Locations (1)

G1J 1Z4

RECRUITING

CHU de Québec-Université Laval (Hôpital de l'Enfant-Jésus), Québec

All Listed Sponsors
collaborator

Canadian Perioperative Anesthesia Clinical Trials (PACT) Group

UNKNOWN

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

International Anesthesia Research Society (IARS)

OTHER

lead

CHU de Quebec-Universite Laval

OTHER